OpenEvidence Advances AI Agents in Oncology and Announces New Models
OpenEvidence is strengthening its oncology capabilities through a partnership with a leading cancer center and introducing new medical AI models named Darwin, Osler, Sackett, and Snow.
OpenEvidence announced that it has partnered with a leading cancer center to develop specialized AI agents for cancer treatment, integrating a precise oncology knowledge base into its platform. The company also unveiled a new family of medical AI models named Darwin, Osler, Sackett, and Snow.
Strategic Partnership in Oncology
OpenEvidence announced that it has entered into a collaboration with a leading cancer center to strengthen its oncology capabilities.
Through this partnership, expert-curated interpretations for cancer genomic alterations are being integrated into the platform.
Vision for Specialized AI Agents
Company founder Daniel Nadler stated that they aim to develop AI agents capable of establishing sub-specialties in clinical fields.
This system is intended to provide a multidisciplinary care team free of charge to physicians in rural or disadvantaged regions.
New Medical AI Models
OpenEvidence introduced a new family of medical AI models named after the founders of modern medicine.
This family includes models with varying speed and depth capacities named Darwin, Osler, Sackett, and Snow.
Performance of the Darwin Model
The company's most advanced model, OpenEvidence Darwin, achieved a perfect score on MedQA, an independent medical benchmark.
The Darwin model is currently in a research preview and is being tested by enterprise partners and accredited researchers.
Models Released for Clinicians
The Osler, Sackett, and Snow models have been made available to all verified clinicians.
While Osler serves as the platform's default model providing fast responses, Sackett and Snow perform deeper research.